Verastem Oncology has announced updated efficacy and safety results from GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375 (VS-7375 outside China), an oral KRAS G12D inhibitor, in patients with advanced KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC). The data were presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Among 59 efficacy-evaluable, heavily pre-treated patients receiving 600 mg daily, the overall response rate was 40.7%, and the disease control rate was 96.7%. At month four, the observed overall survival rate was 92.2%, with median overall survival not reached as of the data cutoff. The median progression-free survival was 5.52 months. The study reported a manageable safety profile, with a 4% discontinuation rate due to adverse events. At the time of evaluation, 47% of patients remained on treatment.